share_log

12 Health Care Stocks Moving In Tuesday's Intraday Session

Benzinga ·  Feb 28 01:31

Gainers

  • Janux Therapeutics (NASDAQ:JANX) stock increased by 189.9% to $43.78 during Tuesday's regular session. The company's market cap stands at $2.0 billion.
  • Viking Therapeutics (NASDAQ:VKTX) shares moved upwards by 91.96% to $73.87. The company's market cap stands at $7.4 billion.
  • CytomX Therapeutics (NASDAQ:CTMX) shares moved upwards by 41.81% to $2.34. The company's market cap stands at $156.7 million.
  • Biora Therapeutics (NASDAQ:BIOR) shares rose 33.24% to $1.4. The market value of their outstanding shares is at $38.0 million.
  • Codexis (NASDAQ:CDXS) shares increased by 31.4% to $4.21. The company's market cap stands at $293.6 million.
  • Hims & Hers Health (NYSE:HIMS) shares moved upwards by 31.02% to $13.43. The company's market cap stands at $2.8 billion. As per the news, the Q4 earnings report came out yesterday.

Losers

  • Minerva Neurosciences (NASDAQ:NERV) stock decreased by 57.1% to $2.92 during Tuesday's regular session. The market value of their outstanding shares is at $20.4 million. As per the news, the Q4 earnings report came out 3 days ago.
  • NRX Pharmaceuticals (NASDAQ:NRXP) stock declined by 32.77% to $0.29. The company's market cap stands at $24.4 million.
  • Calidi Biotherapeutics (AMEX:CLDI) shares decreased by 24.93% to $0.91. The market value of their outstanding shares is at $32.2 million.
  • Telesis Bio (NASDAQ:TBIO) stock fell 21.22% to $0.52. The company's market cap stands at $15.5 million.
  • Qualigen Therapeutics (NASDAQ:QLGN) shares decreased by 15.21% to $0.49. The company's market cap stands at $2.5 million.
  • SI-BONE (NASDAQ:SIBN) stock decreased by 14.15% to $17.64. The market value of their outstanding shares is at $714.2 million. The company's, Q4 earnings came out yesterday. See Also:

This article was generated by Benzinga's automated content engine and reviewed by an editor.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment